Where does the market go from here? Will retail investors sell?

What’s the deal with GE?

We changed our name and Amazon announced their new locations!

A $500 Million Biotech IPO. Amarin Data

Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision.

Why cost should only be one consideration

S&P Companies not as negative; Gene Therapy manufacturing is stretched thin

Lessons from Halloween when your kids have peanut allergies

Swimming and the Dow Jones

President’s Drug Pricing Speech and New CA Sexual Harassment Law

M&A Activity - Will Market Forces Play a Role?

Episode 36 - Concept or Concrete?

Episode 35 - McDermott Will & Emery Dealmaking Symposium Recap

Episode 34 - DeviceTalks Recap

Episode 33 - Chinese Espionage and Cyber Coverage

Episode 32 - Can the Biotech IPO Market Sustain Itself?

I’m Doing an IPO and My D&O Insurance is Expensive

FDA Condemns Undamaged Product - Insurance Should Have Paid

Episode 29 - MD Bio-Tech Conference Recap

Episode 28 - NJTC CFO Forum Recap